Frailty Is the New Cardiovascular Risk Factor — And Researchers Are Learning to Engineer Against It

The shift is being driven by two ideas converging at once. The first is that people of the same chronological age can be biologically decades apart, and frailty captures that gap better than a birthday does. The second is that the levers that move frailty — muscle, mitochondria, inflammation, nutrition — are increasingly the same levers researchers believe move cardiovascular risk. A Canadian trial now enrolling older Nova Scotians is built explicitly on that logic, proposing that a comprehensive strategy targeting diet and physical activity to reduce frailty will, in turn, reduce the risk of cardiovascular disease. Frail people, the investigators note, are more likely to develop heart disease, more likely to have complications, and more likely to die of it than fit people of the same age — independent of the traditional risk factors.

The implication is uncomfortable and clarifying at the same time. A perfect lipid panel is not a complete picture if you cannot rise from a chair without using your arms.

The most authoritative recent statement on how older adults should actually move comes from the International Conference on Frailty and Sarcopenia Research (ICFSR). Their global consensus review argues that physical activity and exercise meaningfully modulate the aging phenotype itself — that movement can prevent or ameliorate lifestyle-related diseases, extend health span, enhance physical function, and reduce the burden of non-communicable chronic diseases including cardiometabolic disease, cancer, musculoskeletal and neurological conditions, and chronic respiratory diseases, as well as premature mortality.

That sentence is doing a lot of work, and it is worth slowing down on. The authors are not claiming exercise is a cure for any one of those conditions. They are claiming it influences the underlying biology of aging — what geroscientists call the cellular and molecular drivers — and that the downstream effect is broad. In their framing, structured exercise prescriptions should be customized and monitored like any other medical treatment, considering dose-response relationships and the specific adaptations necessary for intended outcomes.

What does the prescription look like? A multifaceted regimen: aerobic, resistance, balance, and flexibility training, delivered through both structured workouts and incidental lifestyle activity. None of these components is optional. Walking is not enough on its own; neither is yoga; neither is the once-a-week resistance class. The consensus is that each addresses a different layer of decline, and that older adults should be assembling all four.

The Nova Scotia Health Authority trial, formally listed as NCT06693271, takes the consensus seriously and then adds food. Its premise is that the degree of frailty can be modified by lifestyle interventions — that sedentary lifestyles, food insecurity, and suboptimal dietary habits can exacerbate frailty, whereas diet and exercise interventions can attenuate it. The intervention layers three things: adequate dietary protein (which older adults frequently under-consume), wild blueberries (a regional crop unusually rich in anthocyanins, the polyphenols linked to vascular and metabolic benefits), and a supervised exercise program.

What makes the design notable is its explicit attention to sex differences. The investigators point out that older women are frailer than men and tend to express cardiovascular disease differently than men, but whether the relationships between frailty and CVD are sex-specific is unclear. That is a real gap. Heart disease has historically been studied as a male phenomenon, and frailty has historically been studied as a geriatric one. The Nova Scotia trial is one of the few designed to interrogate the intersection.

One mechanism the researchers are watching is chronic inflammation — the smoldering, low-grade kind sometimes called inflammaging. They hypothesize that shared pathophysiological mechanisms such as chronic inflammation may help explain the links between cardiovascular disease and frailty. If diet and exercise together can lower that inflammatory tone, the cardiovascular benefit may not be separate from the anti-frailty benefit — it may be the same benefit, measured two ways.

If the Nova Scotia study sits at the food-and-movement end of the spectrum, a trial out of Massachusetts General Hospital sits at the pharmacology end. NCT06554717 is testing tesamorelin, a growth-hormone-releasing hormone analogue already FDA-approved for abdominal fat accumulation in people with HIV, as an adjunct to exercise for physical function. The rationale is that this population offers a kind of natural experiment in accelerated aging. People with HIV experience earlier impairments in physical function compared to the general population, with an earlier presentation and more rapid development of frailty — a multisystemic syndrome characterized by reduced activity, fatigue, slowness, weakness, and weight loss.

Importantly, exercise alone has limits here. The investigators note that while exercise can improve physical function in people with HIV, it is less effective at doing so than in the general population and is difficult to sustain long-term. That is the gap they are trying to close. Tesamorelin has already been shown to increase muscle mass and improve measures of muscle health, but its effects on physical performance and muscle strength have not yet been evaluated. The trial pairs the medication (or placebo) with a coached, home-based exercise program for 24 weeks, then watches what happens during a 24-week off-drug extension.

It is worth being clear-eyed about what this means for readers without HIV. This is not a longevity drug arriving at the pharmacy counter. It is a precise, mechanistic question being asked in a specific population, with the broader implication that drug-plus-exercise combinations may eventually be a category we take seriously for aging itself. For now, the takeaway is conceptual: the same biology — muscle, hormones, inflammation — keeps showing up at the center of the frailty story.

It is tempting, reading three studies together, to declare frailty solved. It is not. The ICFSR document is a consensus review, not a single randomized trial; the Nova Scotia and Massachusetts General studies are protocols whose primary results are still ahead of us. What is reasonable to say, today, is that the direction of travel is consistent. Frailty looks increasingly like a cardiovascular risk factor that responds to the same levers — movement, nutrition, and in select cases pharmacology — that we already know matter for aging biology more broadly.

The practical implication for readers is less dramatic than the science. The strongest, most replicated tool in the kit is still structured, varied exercise, ideally with a resistance component that most older adults skip. Adequate protein and a diet built around whole, polyphenol-rich foods is the supporting cast that early trials are now formally testing. Medication-plus-exercise combinations are a frontier worth watching, not a shelf to shop from. The women being studied in Nova Scotia, and the participants enrolling in Boston, are doing the work that will tell us, in a few years, how much further we can push.

What has already shifted is the framing. Frailty is no longer the inevitable backdrop of aging. It is a target. And the early signals suggest that the price of admission — sustained, structured movement, deliberate eating, and refusing to be dismissed by a healthcare system that has historically under-measured these things in women — is one many readers are ready to pay.